drugset
drugset / Trial / NCT07258121

Study of ZGGS34 in Participants With Advanced Solid Tumors

NCT07258121 ↗

Phase 1/2 Recruiting 400 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a multicenter, open-label Phase 1/2 study in participants with advanced solid tumors. The study consists of two parts: Part 1 is a dose-escalation phase to evaluate the safety and tolerability of ZGGS34 in advanced solid tumor participants; Part 2 is a cohort-expansion phase to assess the efficacy and safety of ZGGS34 (± chemotherapy) in selected MUC17-positive advanced solid tumor participants.

Timeline

Start
2025-12-31
Primary completion
2028-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ZG006 Unknown 0.5 mg Intravenous
Subject ZG006 Unknown 1.5 mg Intravenous
Subject ZG006 Unknown 5 mg Intravenous
Subject ZG006 Unknown 15 mg Intravenous
Subject ZG006 Unknown 30 mg Intravenous
Subject ZG006 Unknown 60 mg Intravenous
Subject ZG006 Unknown 100 mg Intravenous

Indications

cancer